X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Arakoda (tafenoquine succinate) is a USFDA approved small molecule drug which acts as a viral replication inhibitor. It is being evaluated for the treatment of candida auris infection.
Lead Product(s): Tafenoquine Succinate
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The Company intends to use the net proceeds for the relaunch of the Company’s FDA-approved Arakoda (tafenoquine) an antimalarial indicated for the prophylaxis of malaria in. patients aged 18 years and older.
Lead Product(s): Tafenoquine Succinate
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: WallachBeth Capital LLC
Deal Size: $2.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 30, 2024
Details:
ARAKODA (tafenoquine) has not been proven safe to treat or prevent COVID-19. Testing for G6PD (Glucose6-phosphate dehydrogenase deficiency) is mandatory before prescribing ARAKODA.
Lead Product(s): Tafenoquine Succinate
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
Data from the TEACH study of tafenoquine, an 8-aminoquinoline, for the prevention of relapse of Plasmodium vivax (P. vivax) malaria in children and adolescents showed 95% of the study’s 60 subjects had no recurrence of P. vivax malaria during four months of follow-up.
Lead Product(s): Tafenoquine Succinate
Therapeutic Area: Infections and Infectious Diseases Product Name: Krintafel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
